In a genome-wide CRISPR/Cas9 screen, Burr et al. demonstrated that genetic or pharmacologic inhibition of PRC2 restored MHC-I expression and reinstated CD8+ T-cell-mediated tumor control in vivo [122]. The gene discussed is CD8A; the disease is neoplasm.